NUP214 and acute myeloid leukemia: We observed that the 2-year cumulative incidence of relapse after allo-HSCT was only 14.3% in AML patients with DEK-NUP214, which was comparable to that in intermediate- or high-risk AML patients without DEK-NUP214.